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Summary
In this work, we aimed to evaluate the levels of ferritin enriched in H
subunits (H-ferritin) and ferritin enriched in L subunits (L-ferritin) and the
cells expressing these two molecules in the lymph node (LN) biopsies
obtained from adult-onset Still’s disease (AOSD) patients, and the possible
correlation among these data and the severity of the disease. Ten patients
with AOSD underwent LN biopsy. All the samples were stained by
immunofluorescence. A statistical analysis was performed to estimate the
possible correlation among both H-ferritin and L-ferritin tissue expression
and the clinical picture of the disease. Furthermore, the same analysis was
performed to evaluate the possible correlation among the number of
CD681/H-ferritin1 or CD681/L-ferritin1 cells and the clinical picture.
Immunofluorescence analysis demonstrated an increased tissue H-ferritin
expression in the LNs of AOSD patients. This increased expression
correlated with the severity of the disease. An increased number of CD68
macrophages expressing H-ferritin was observed in the LN samples of our
patients. Furthermore, we observed that the number of CD681/H-ferritin1
cells correlated significantly with the severity of the clinical picture. Our
data showed an imbalance between the levels of H- and L-ferritin in LNs of
AOSD patients and the evidence of an increased number of CD681/
H-ferritin1 cells in the same organs. Furthermore, a correlation among both
the tissue H-ferritin levels and the CD681/H-ferritin1 cells and the clinical
picture was observed.
Keywords: adult-onset Still’s disease, H-ferritin, hyperferritinaemic syn-
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Introduction
Adult-onset Still’s disease (AOSD) is a rare systemic inflam-
matory disorder of unknown aetiology, characterized by
quotidian high spiking fevers, arthritis and multi-organ
involvement, requiring immunosuppressive therapies [1–3].
A large percentage of AOSD patients showed an evanescent
salmon-pink or erythematous maculopapular eruption
which appears frequently during febrile attacks, and is found
predominantly on the proximal limbs and trunk [3,4]. Fur-
thermore, both splenomegaly and mild–severe enlargement
of cervical lymph nodes (LNs) are observed frequently in
AOSD patients and lymphoma should be always considered
in the differential diagnosis of this clinical picture [1–4].
Recently, it has been suggested that AOSD and other
uncommon medical conditions such as macrophage activa-
tion syndrome (MAS), catastrophic anti-phospholipid syn-
drome and septic shock, which share similar clinical and
laboratory features, may be considered an intermediate
phenotype of the same inflammatory process, affecting tar-
get cells killed by cytotoxic T cells and natural killer (NK)
cells [5]. In this context the cytokine storm observed in
these conditions, associated with hyperferritinaemia, may
further activate both NK and cytotoxic T cells with conse-
quent release of uncontrolled granzyme system and per-
forin release, thus amplifying the cytokine storm and the
production of proinflammatory cytokines [6,7].
Ferritin is an intracellular iron storage protein including
24 subunits: heavy (H) subunits and light (L) subunits on
the bases of their molecular weight [8,9]. The H-/L-subunits
ratio may change, depending on the specific tissue and the
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physiological status of the cell. In normal conditions, ferri-
tin enriched in L subunits (L-ferritin) has been found in the
liver and in the spleen; on the contrary, the ferritin enriched
in H subunits (H-ferritin), may be observed mainly in the
heart and kidneys [8,9]. Although the secretory pathway of
serum ferritin has not been clarified fully, hepatocytes, mac-
rophages and K€upffer cells may be involved in its secretion
[8–11].
For many years, ferritin has been considered as a potential
immunosuppressant, inducing suppression of delayed-type
hypersensitivity [12], suppression of antibody production by
B lymphocytes [13], decreasing the phagocytosis by granulo-
cytes [14] and regulating granulo-mono-cytopoiesis. More
recently, it has been suggested that H-ferritin induces pro-
duction of the anti-inflammatory cytokine in lymphocytes
[15] and may act as a negative regulator of the CXC chemo-
kine receptor 4 (CXCR4), impairing the signalling leading to
the activation of mitogen-activated protein kinase (MAPK),
a kinase that is known to play an important role in cell
proliferation, differentiation and migration [16].
Intriguingly, in recent years, a proinflammatory role of
extracellular ferritin has been suggested for some specific
cells, such as hepatic stellate cells [17]. Cells treated with fer-
ritin activate PI3 kinase phosphorylation, protein kinase C
zeta activation and MAPK activation, culminating in
nuclear factor-kappa B (NF-jB) activation. This activation
leads to the production of proinflammatory molecules,
inducible nitric oxide synthase and others. Of note, this
function is independent of the iron content of ferritin, sug-
gesting that exogenous ferritin may play active roles inde-
pendently of its main function [17]. In fact, ferritin
synthesis may be regulated not only in response to iron
availability, but also by different inflammatory cytokines
such as interleukin (IL)-1b and IL-6, and by different bio-
logical stimuli such as oxidative stress, hypoxia–ischaemia,
hyperoxia and lipopolysaccharide (LPS) toxicity [7,9–11].
H-ferritin specifically binds a member of the T cell immu-
noglobulin and mucin-domain (TIM) gene family, TIM-2
[7], which is considered a defined marker of T helper type 2
(Th2) cells [17–19]. During the inflammatory response
other cells, including macrophages, may express TIM-2 on
their surface [18–23]. In this setting, instead of modulating
down-regulation of the immune response, as observed in
normal conditions, the H-ferritin/TIM-2 binding up-
regulates strongly the expression of inflammatory cytokines,
playing a pivotal role in the development of an extremely
severe condition known as a ‘cytokine storm’ [7–11].
Although a growing body of evidence suggests that mac-
rophages are associated with the immunopathogenic mech-
anism of this rare condition, at present their exact role is
not fully understood [1,7]. It is well known that, together
with other myeloid and lymphoid cells, macrophages in the
subcapsular sinus and medulla of secondary LNs contrib-
ute to the innate and adaptive responses of the host, shap-
ing the nature and quality of inflammation [24].
In this paper, we show both an increased tissue expres-
sion of H-ferritin and an increased number of CD681/
H-ferritin1 macrophages in the LNs of AOSD patients, and
these results correlate with the disease activity and the
serum ferritin levels of the same patients, suggesting a
pathogenic role of these macrophages in this inflammatory
disease.
Patients and methods
In the last 10 years, 10 consecutive patients with AOSD
referred to the Rheumatology Clinic of L’Aquila University
and to the Rheumatology Clinic of Palermo University
were enrolled into this study. All patients fulfilled the crite-
ria proposed by Yamaguchi et al. [25] for AOSD and
showed a flare of the disease in the context of a polycyclic
or a chronic form of the disease, according with the criteria
proposed by Cush et al. [26]. Serum levels of ferritin, eryth-
rocyte sedimentation rate (ESR) and C-reactive protein
(CRP) were obtained from the patients. Pouchot’s score
was used to evaluate the disease activity [27]. This score
ranges from 0 to 12 and is calculated by assigning and add-
ing 1 point for each of the following manifestations occur-
ring during a disease flare: fever, evanescent rash, pleuritis,
pneumonia, pericarditis, hepatomegaly or abnormal liver
function tests, splenomegaly, lymphadenopathy, white
blood cells> 15 000/mm3, sore throat, myalgias and
abdominal pain. The demographic data of our patients are
reported in Table 1.
Ten LN samples were collected from patients who had
undergone biopsies for differential diagnosis with a lym-
phoproliferative disease. These samples were matched with
LN samples obtained from subjects without any symptoms
or history for autoimmune or autoinflammatory diseases
who had undergone biopsies to exclude lymphoprolifera-
tive or granulomatous diseases.
The San Salvatore University Hospital ethics committee
approved this study. It was performed according to Good
Clinical Practice guidelines, and written informed consent
Table 1. Demographic data of adult-onset Still’s disease (AOSD)
patients.
Women (men) 5 (5)
Disease duration, median (range) months 19 (15, 30)
Polycyclic form (chronic form) 5 (5)
Serum ferritin, median (range) ng/ml 14765 (734, 3021)
Erythrocyte sedimentation rate mm/h 82 (54, 120)
C-reactive protein mg/dl 31 (12, 150)
White blood count 10/ml 155 (101, 189)
AST U/l 82 (10, 101)
ALT U/l 110 (41, 154)
Pouchot’s score 6 (4, 10)
ALT5alanine transaminase; AST5aspartate transaminase.
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was obtained from all patients according to the Declaration
of Helsinki.
Histological analysis of biopsies
Sequential sections (thickness 3 mm) were obtained from
LN biopsies, fixed by formaldehyde and paraffin-
embedded. For conventional smear preparations, glass
smear slides were fixed with 95% ethanol for at least 15
min, and then treated with water for 1 min, haematoxylin
for 1 min, running water for 15 min, eosin for 30 s, 95%
ethanol for 10 min and 100% ethanol for 10 min. Stained
slides were coverslipped with Permount. Haematoxylin and
eosin images were acquired using an Olympus BX53 fluo-
rescence microscope with CellSens software (Olympus
America Inc., Center Valley, PA, USA).
For immunofluorescence, antigen retrieval was carried
out using target retrieval solution (Dako, Glostrup, Den-
mark). Sections were treated with Dako protein block
to block non-specific binding and successively with
H-ferritin, L-ferritin and CD68 antibodies. Ferritin L chain
(H-45, sc-25616; Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) is a rabbit polyclonal antibody [immuno-
globulin (Ig)G] raised against amino acids 131–175 of the
human-origin ferritin L chain. The ferritin H chain (B-12,
sc-376594; Santa Cruz Biotechnology Inc.) is a mouse
monoclonal antibody (IgG2a) raised against amino acids
131–183 of the human-origin ferritin H chain. The immu-
noreaction was revealed by using a fluorescence secondary
antibody (Alexa Fluor 488-conjugated and Alexa Fluor
555-conjugated; Invitrogen, Carlsbad, CA, USA) and
negative controls were obtained by omitting the primary
antibody. Cell nuclei were visualized using 40,6-diamidino-
2-phenylindole (DAPI). Sections were examined and pho-
tographed under a light microscope (Olympus BX53).
Immunofluorescence images were acquired using an Olym-
pus BX53 fluorescence microscope with CellSens software
(Olympus America Inc.).
Fluorescence was analysed using an Olympus BX53 fluores-
cence microscope and the immunofluorescence optical den-
sity was performed using ImageJ software (NIH, Bethesda,
MD, USA). The number of CD681/H-ferritin1 and CD681/
L-ferritin1 cells was determined as follows: 10 random high-
power microscopic fields for each area (10 000 lm2) were
selected and the numbers of CD681/H-ferritin1 and CD681/
L-ferritin1 cells were counted using NIH ImageJ version 143
(http://rsbweb.nih.gov/ij/) freeware.
Statistical analysis
GraphPad Prism version 50 software was used for statisti-
cal analyses. Results are expressed as median (range).
Due to the non-parametric distribution of our data, the
Mann–Whitney U-test was used as appropriate for analy-
ses. Spearman’s correlation analysis and linear regression
were performed to evaluate possible correlations between
the tissue expression of H- and L-ferritin and the number
of CD681/H-ferritin1 cells or CD681/L-ferritin1 cells and
clinical and laboratory data. Statistical significance was
expressed by a P-value< 005.
Results
Increased expression of H-ferritin
Immunofluorescence analysis shown in Fig. 1a shows an
increased extracellular H-ferritin expression in the LN
samples of AOSD patients when compared with healthy
controls (HC). Conversely, the results in Fig. 1b concerning
L-ferritin do not show increased immunofluorescence
expression in AOSD patients when compared to HC. The
quantitative analyses of the optical density for both H- and
Fig. 1. Increased expression of H-ferritin in lymph node (LN) samples of adult-onset Still’s disease (AOSD) patients. Immunofluorescence analyses in LN
sample of subcapsular sinus shows: (a) increased H-ferritin expression in AOSD patients when compared with healthy controls (HC) (d). No increase of L-
ferritin (b) has been detected in patients when compared with HC (e). (g) H-ferritin expression levels are significantly higher when compared with the
levels of L-ferritin (***P< 0001) (c) (f) no co-localization between H- and L-ferritin has been shown in both AOSD patients and HC.
H-ferritin expression in the LNs of AOSD patients
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L-ferritin expression showed a significant increase of H-
ferritin when compared with both L-ferritin in AOSD
patients and with HC (P< 0001; P< 0001, respectively)
(Fig. 1g).
Correlation of H-ferritin with clinical features
Our analyses showed a positive correlation between the
increased levels of extracellular H-ferritin in the LN tissues
and disease activity. H-ferritin tissue levels, showing the
classical granular deposition in the tissue, correlated
strongly with both Pouchot’s score and serum ferritin
(P< 00001; P< 00001, respectively). Furthermore, there
was a positive correlation between these levels of H-ferritin
and ESR (P< 005; P< 005, respectively). No correlation
was found between CRP and H-ferritin. Figure 2 shows the
linear regression performed among these parameters. Of
note, correlation analyses concerning L-ferritin tissues and
the same parameters did not show significant results.
CD681/H-ferritin1 cells in LNs from AOSD patients
In the histological analyses of LN samples, performed
according to Jeon et al. [28], two patterns were observed.
The atypical paracortical hyperplasia pattern was character-
ized by paracortical hyperplasia with vascular proliferation
and mixed cell infiltration in five patients (Fig. 3a), and the
burnt-out histiocytic pattern was characterized by exuber-
ant paracortical hyperplasia with vascular proliferation and
extensive sinus macrophage infiltration in the other five
patients (Fig. 3b). The immunofluorescence analysis
showed that CD681/H-ferritin1 cells, with enlarged cyto-
plasm, were distributed widely in the LN tissue of AOSD
patients (Fig. 4b), without specific localization in both the
subcapsular and medullary sini, which represent the areas
colonized normally by resident macrophages in the LNs.
With regard to L-ferritin, no co-localization with CD68
molecule was observed in our patients.
Correlation of number of CD681/H-ferritin1 cells
in LN with disease activity
A significantly increased number of CD681/H-ferritin1
cells was observed in LNs of AOSD patients when com-
pared with HC [AOSD: 4.5 (35, 58) versus HC: 06 (02,
12); P< 00001]. In addition, a significant correlation
between the number of H-ferritin1/CD681cells and Pou-
chot’s score was observed (P< 001). Furthermore, we
demonstrated a strong positive correlation between the
number of CD681/H-ferritin1 cells and serum ferritin
(P< 00001). Conversely, as shown in Fig. 5, no significant
correlations were observed among the number of CD681/
H-ferritin1 cells and ESR and CRP.
Fig. 2. Correlation of H-ferritin in lymph nodes (LNs) and different markers of severity of adult-onset Still’s disease (AOSD) patients. The non-
parametric Spearman’s r correlation coefficient is calculated.
Fig. 3. The histological analyses
of lymph node (LN) samples.
The haematoxylin and eosin
analysis of LN samples shows:
(a) the atypical paracortical
hyperplasia pattern and (b) the
burnt-out histiocytic pattern.
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Discussion
In this work, we have shown that both the H-ferritin tissue
expression and the number of CD681/H-ferritin1 cells
were increased in the LNs of AOSD patients, and these
results correlated significantly with disease severity. To our
knowledge, this is the first work that has aimed to investi-
gate the evidence of these cells in secondary lymphoid
organs during AOSD.
It has been proposed recently that AOSD, MAS, cata-
strophic anti-phospholipid syndrome and septic shock
should be included in ‘hyperferritinaemic syndrome’, in
which the higher levels of ferritin may be considered to be
not only a consequence of the inflammation, but are prob-
ably involved in a vicious loop leading to the cytokine
storm [5]. The release during erythrophagocytosis, the
impaired tissue clearance by macrophages and the secretion
of ferritin by these cells have been considered as possible
causes of hyperferritinaemia in these patients [29,30].
As mentioned previously, we reported an increased
number of CD681/H-ferritin1. In this context, it is well
known that macrophages are distributed widely through-
out the body, performing vital homeostatic and defence
functions after local and systemic perturbation within tis-
sues. Macrophages are central players in innate and adapt-
ive defence reactions, directly neutralizing pathogens by
phagocytosis and orchestrating the responses of other
immune cells [31]. In response to local adaptation, tissue
macrophages display different functional specializations
which is reflected in their phenotype, as well as gene
expression profiles [31]. Basically, subcapsular sinus
Fig. 4. CD68 macrophages
expressing H-ferritin in lymph
node (LN) samples of adult-onset
Still’s disease (AOSD) patients.
The hematoxylin eosin analysis of
LNs samples of medullary sinus
in AOSD patients (a) and HC
(c). The immunofluorescence
analysis in LN sample of
medullary sinus shows: (b) CD68
macrophages expressing H-
ferritin.
Fig. 5. Increased number of CD681/H-ferritin1 cells and correlation with severity of adult-onset Still’s disease (AOSD). (a) An increased number
of CD681/H-ferritin1 cells in lymph node (LN) samples of AOSD patients when compared to healthy controls (HC) (***P< 0001). (b,c) The
non-parametric Spearman’s r correlation coefficient is calculated.
H-ferritin expression in the LNs of AOSD patients
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macrophages (SSMs) and medullary sinus macrophages
(MSMs) in the LNs have been recognized [24,31]. The role
of SSMs and MSMs in immune response has been studied
extensively [32,33]. SSMs may capture lymph-borne
substances, including virus particles, through different
mechanisms, including lectins, scavenger receptors and
CR3, but are poorly endocytic. Antigens and immunocom-
plexes bind to SSM heads, are translocated without inter-
nalization to their tails, and are finally presented to
follicular B cells, migrating randomly through the dense
net of tails. Cognate B cells are activated directly from
SSMs via the B cell receptor [24,31]. In contrast, MSMs
recognize and transfer antigens into conspicuous phagoly-
sosomes. Furthermore, MSMs play an important role in
determining survival and clearance of short-lived early
immune cells [24,31–33].
In our study, we observed that the CD681/H-ferritin1
cells were distributed widely in the tissue, without specific
colonization of the subcapsular and/or medullary sini,
which are the specific resident macrophage areas in the
LNs [24]. The majority of these resident macrophages are
established prenatally, and these cellular compartments
self-maintain locally independently from each other within
their tissue of residence and are self-sufficient and inde-
pendent of further haematopoietic input [31–33]. In con-
trast, our data suggest that the CD681/H-ferritin1 cells are
part of the additional CD681 macrophage pool of LN mac-
rophages, including interfollicular cells, which migrate into
the LNs after immune activation, under the influence of
inflammatory stimuli, and interact with various innate and
adaptive cells [24,31–33]. Although our study does not
address the origin of H-ferritin in LN tissue, our results
might allow us to speculate that during AOSD, migratory
macrophages colonizing the LNs may produce and secrete
ferritin, thus leading to the release of inflammatory media-
tors [7]. In fact, it has been shown that macrophages may
produce ferritin in an animal model, and after inflamma-
tory stimuli macrophages may release H-ferritin [34–37].
Furthermore, it must be pointed out that IL-1, IL-6, inter-
feron (IFN)-g and tumour necrosis factor (TNF)-a, largely
over-expressed in AOSD patients [1,5,38], may induce the
expression of H-ferritin [34,35] via Fer2 activation, which
is able to stimulate the synthesis of H-ferritin and further
production of many proinflammatory cytokines, thus
perpetuating the inflammatory state [11,36,37,39,40]. The
experimental evidence reported in previous studies
strongly supports our data of increased production of
H-ferritin during AOSD, which is characterized by elevated
levels of proinflammatory cytokines [1,5,34–40].
Recently, ferritin distribution was shown in the B area of
germinal centres in LN samples from one patient with
AOSD [41], and the authors suggested that ferritin may act
as an antigen in AOSD enhancing the inflammatory
response via the activation of B cells and ferritin autoanti-
body production [41], although their presence in AOSD
has still not been confirmed as observed in other diseases
[42,43].
In our work, both the increased H-ferritin levels in LNs
and the number of CD681/H-ferritin1 cells colonizing the
lymphatic tissue correlated significantly with disease activ-
ity and serum ferritin, and these data mirror what has been
observed with other biomarkers of macrophage activation,
such as macrophage–colony-stimulating factor, IFN-g,
sCD163 and macrophage inhibitory factor, which corre-
lates significantly with the AOSD activity [41,44–46]. It
should be pointed out that LNs are highly dynamic struc-
tures: during immune response there is a continuous quick
entry of lymphocytes and macrophages from the blood-
stream via the afferent lymphatics and a slow egress of
recirculating lymphocytes and effector cells via the efferent
lymphatics, determining LN enlargement [47,48], as
reported frequently during AOSD [5,6,49]. In this context,
the finding of increased CD681/H-ferritin1 cells in the
affected LNs and the strong correlation between the num-
ber of cells and the severity of disease may allow us to sup-
pose that these cells may be involved in the pathogenic
mechanism of AOSD and confirm our previous results, in
which CD681/H-ferritin1 cells, infiltrating the bone mar-
row, correlated strongly with the mortality of MAS-
associated AOSD patients [50].
It has been suggested recently that AOSD may be catego-
rized as a multi-genic inflammatory disorder at the cross-
roads of autoinflammatory and autoimmune diseases [51].
In fact, it has been suggested that IL-18 and IL-1b, which
are processed through the inflammasome machinery, may
play an important role in AOSD pathogenesis, modulating
both IL-6 and Th1 cytokine secretion as well as NK cell
dysregulation and macrophage activation [51]. According
to our results we might speculate that the activated
CD681/H-ferritin1 cells, via the production and secretion
of large amount of H-ferritin, which display a proinflam-
matory function, may amplify the up-regulation and pro-
duction of inflammatory mediators.
In conclusion, our observational study shows an
increased level of extracellular H-ferritin in the lymphatic
tissue of AOSD patients, associated with a CD681/
H-ferritin1 macrophage colonization of the same tissue.
Although our study does not address the origin of
H-ferritin in these affected tissues, the strong correlation of
these data with the severity of disease suggests a pathogenic
role of H-ferritin and H-ferritin-expressing macrophages
during this disease. Further studies are ongoing in our lab-
oratory in order to elucidate more thoroughly the role of
these cells and H-ferritin in AOSD.
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